Following a year of collaboration under a joint venture agreement, US-based TKI and Cyprus-based Hybrid ConsulTech have ...

Manojkumar Bupathi, MD, MS, discussed his takeaways on physician decision-making for frontline metastatic renal cell carcinoma (RCC) treatment from a Case-Based Roundtable event.

How Targeted Approaches Are Changing Management of Advanced EGFR-Mutant Lung Cancer and Pavingthe Way for ...

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ('Kelun-Biotech', 6990.HK) today announced that results from its ...

While metastatic gastrointestinal stromal tumours (GIST) are generally treated using systemic therapy, surgery and/or ablative procedures, radiotherapy appears to have a restricted role. We present a ...

J INTS BIO, a company specializing in the development of therapeutics for cancer and rare diseases, officially announced ...

JIN-A02 is an oral, fourth-generation EGFR-TKI designed to overcome resistance mutations (such as C797S) that develop after treatment failure with third-generation EGFR-TKIs, which are currently ...

In a recent study, researchers have uncovered the biological trigger behind the dangerous immune-related adverse events (irAEs) that occur when the ...

In its first global phase 3 readout, Akeso and Summit Therapeutics’ closely watched PD-1xVEGF bispecific antibody ivonescimab ...

SEOUL, South Korea , June 1, 2025 /PRNewswire/ -- J INTS BIO, a company specializing in the development of therapeutics for cancer and rare diseases, officially announced interim results from ...